Valuation: Sera Prognostics, Inc.

Market Cap 77.14M 67.48M 62.24M 57.48M 109M 7.36B 111M 744M 292M 3.62B 290M 283M 12.46B P/E 2026 *
-3.01x
P/E 2027 * -3.52x
Enterprise Value 77.14M 67.48M 62.24M 57.48M 109M 7.36B 111M 744M 292M 3.62B 290M 283M 12.46B EV / Sales 2026 *
213x
EV / Sales 2027 * 28.8x
Free-Float
86.31%
Yield 2026 *
-
Yield 2027 * -
1 day-4.37%
1 week-1.50%
Current month+8.24%
1 month-1.50%
6 months-46.61%
Current year-33.22%
1 week 1.79
Extreme 1.7901
2.12
1 month 1.72
Extreme 1.725
2.12
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
15.5
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 68 29/11/2021
Director/Board Member 63 01/07/2026
Chairman 74 20/04/2011
Date Insider Type Main position Quantity % Market Cap.
06-11Sell

Chief Financial Officer

-2,037 0.0053%
06-11Sell

Executive/Senior Manager

-4,739 0.0124%
06-11Sell

Chief Technology Officer

-362 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-4.37%-1.50%-28.62%-40.12% 77.14M
+0.62%-0.65%+13.31%+16.89% 23.21B
+0.20%-10.81%+21.04% - 17.59B
-6.34%+4.27%+95.73%+65.91% 3.83B
+0.37%-3.77%+12.19%-27.72% 3.34B
-3.90%-17.29%+160.93%+191.92% 2.14B
+8.36%-2.73%+229.02%+322.46% 2.09B
+7.29%+2.15%-34.44%-42.17% 1.9B
+2.10%-3.30%+3.13%+11.80% 1.67B
+0.27%-7.15%-35.91% - 1.67B
Average +0.46%-3.65%+43.64%+62.37% 5.75B
Weighted average by Cap. +0.37%-4.50%+31.07%+41.12%

Financials

2026 *2027 *
Net sales 362K 317K 292K 270K 513K 34.57M 521K 3.49M 1.37M 17.03M 1.36M 1.33M 58.55M 2.68M 2.34M 2.16M 1.99M 3.78M 255M 3.85M 25.79M 10.13M 126M 10.04M 9.83M 432M
Net income -33.26M -29.09M -26.84M -24.78M -47.03M -3.17B -47.82M -321M -126M -1.56B -125M -122M -5.37B -29.98M -26.22M -24.19M -22.34M -42.39M -2.86B -43.1M -289M -113M -1.41B -113M -110M -4.84B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
10/07/26 $1.970 -4.37% 15,857
09/07/26 $2.060 +0.49% 48,034
08/07/26 $2.050 +1.99% 13,728
07/07/26 $2.010 -3.83% 7,833
06/07/26 $2.090 +4.50% 59,989
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.970USD
Average target price
5.500USD
Spread / Average Target
+179.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock